Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Lowered by CENTRAL TRUST Co

CENTRAL TRUST Co cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 18.6% in the 4th quarter, Holdings Channel reports. The firm owned 1,697 shares of the specialty pharmaceutical company’s stock after selling 389 shares during the quarter. CENTRAL TRUST Co’s holdings in Jazz Pharmaceuticals were worth $209,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JAZZ. Creative Planning grew its holdings in Jazz Pharmaceuticals by 21.7% in the 2nd quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after buying an additional 680 shares in the last quarter. Sanctuary Advisors LLC bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $213,000. SG Americas Securities LLC bought a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $752,000. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares in the last quarter. Finally, Wedmont Private Capital grew its holdings in Jazz Pharmaceuticals by 11.4% in the 3rd quarter. Wedmont Private Capital now owns 4,972 shares of the specialty pharmaceutical company’s stock worth $540,000 after buying an additional 507 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,253 shares of company stock worth $890,594 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $121.63 on Wednesday. The stock has a fifty day moving average of $122.62 and a 200-day moving average of $116.28. The firm has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 0.90 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research analyst reports. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC restated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Read Our Latest Stock Analysis on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.